Literature DB >> 9492440

Alopecia areata associated with myasthenia gravis and thymoma: a case of alopecia with marked improvement following thymectomy and high level prednisolone administration.

N Kamada1, A Hatamochi, H Shinkai.   

Abstract

A 57-year-old Japanese woman who suffered from alopecia areata associated with myasthenia gravis (MG) and thymoma responded well to thymectomy and high doses of glucocorticosteroid administration. Several treatments for alopecia areata including administration of systemic prednisolone were attempted, but loss of hair on the scalp progressed. After thymectomy and high level glucocorticosteroid administration for MG, the lesions on the scalp improved within four weeks. Consequently, we suggest that this thymectomy and high level glucocorticosteroid administration assisted in improving the immune dysfunction causing the alopecic lesions in this patient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9492440     DOI: 10.1111/j.1346-8138.1997.tb02323.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  4 in total

1.  Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study.

Authors:  Chih-Chiang Chen; Yun-Ting Chang; Han-Nan Liu; Yi-Ju Chen
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

2.  Alopecia areata and myasthenia gravis presenting as paraneoplastic phenomena of breast cancer.

Authors:  Charles Dunn; Rajiv Nathoo; Aaron Tauer; Layne Green
Journal:  JAAD Case Rep       Date:  2022-01-06

3.  Surgical Removal of a Thymoma without Myasthenia Gravis Can Have a Therapeutic Effect on Concurrent Alopecia Areata: A Case Report.

Authors:  Yu-Ri Cho; Jung-Hwan Kim; Ki-Ho Kim
Journal:  Ann Dermatol       Date:  2022-08       Impact factor: 0.722

4.  Thyroid disorders associated with alopecia areata in egyptian patients.

Authors:  Ola A Bakry; Mohamed A Basha; Maather K El Shafiee; Wafaa A Shehata
Journal:  Indian J Dermatol       Date:  2014-01       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.